CR2O BV

Their core work

CR2O BV is a Dutch clinical research organization (CRO) specializing in the design and management of clinical trials and preclinical studies in the infectious disease and vaccine space. They provide clinical operations expertise to large European research consortia developing vaccines against influenza, coronaviruses, and other emerging pathogens. Their work spans from preclinical development through Phase 1 clinical trials, including controlled human infection model studies, with a particular focus on improving vaccination strategies for aging populations.

What they specialise in

How they've shifted over time

CR2O's earliest H2020 involvement (GLORIA, 2015) focused on pharmaceutical treatment strategy evaluation — comparing glucocorticoid regimens, a classical clinical trial management task. From 2020 onward, they pivoted sharply into vaccines and infectious diseases, joining three major vaccine consortia (ISOLDA, MANCO, ENDFLU) in rapid succession, likely accelerated by the COVID-19 pandemic. This shift signals a strategic repositioning from general clinical research services toward specialized vaccine development support, particularly for emerging pathogens and next-generation influenza vaccines.

CR2O is concentrating on vaccine clinical trials for infectious diseases, with growing emphasis on next-generation platforms (protein-based, MVA-based) and vulnerable populations — expect them to deepen in pandemic preparedness and geriatric vaccination.

How they like to work

CR2O exclusively participates as a consortium partner rather than leading projects, which is typical for a specialized CRO that provides clinical operations expertise to research-driven consortia. With 36 unique partners across 15 countries from just 4 projects, they operate in large, diverse consortia and appear comfortable integrating into complex multi-national teams. Their consistent participant role and substantial funding shares (averaging EUR 2.5M per project) suggest they take on significant clinical trial workpackages rather than minor supporting roles.

CR2O has built a broad European network of 36 unique partners spanning 15 countries through just 4 projects, indicating they consistently join large consortia with diverse membership. Their network is heavily concentrated in the health and vaccine research community across Western and Southern Europe.

What sets them apart

As a private SME providing clinical research organization services within EU-funded vaccine consortia, CR2O fills an essential but uncommon niche: bridging academic vaccine research and the regulatory-compliant clinical trial execution needed to advance candidates into human studies. Their ability to secure substantial funding portions (up to EUR 4.4M in ENDFLU) as a small company suggests they deliver high-value clinical operations that academic partners cannot easily replicate in-house. For consortium builders, CR2O offers an experienced CRO partner already familiar with H2020/Horizon Europe administrative and clinical trial requirements.

Highlights from their portfolio

• ENDFLU
  Largest single project (EUR 4.4M to CR2O) evaluating next-generation influenza vaccines through preclinical development and Phase 1 clinical trials with controlled human infection models.
• MANCO
  Rapid-response COVID-19 project developing monoclonal antibodies against SARS-CoV-2, demonstrating CR2O's ability to mobilize quickly for pandemic threats.
• ISOLDA
  Addresses the critical challenge of vaccine effectiveness in aging populations, covering multiple pathogens (influenza, TBEV, Yellow Fever, MERS-CoV) in a single comprehensive study.